AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-32683084_ITM" title="Facts and information about Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome.">Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome.</a>

Close Set up an RSS feed that alerts you when new articles from PR Newswire are available.

Frequently asked questions about RSS feeds

Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome.

PR Newswire

| August 21, 2007 | COPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

BOSTON and THE WOODLANDS, Texas, Aug. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. presented data today describing the structure-activity relationship (SAR) of a class of internally-developed compounds that includes LX1031 and other compounds under evaluation by the company as potential treatments for irritable bowel syndrome (IBS) and other gastrointestinal disorders. LX1031 is currently under evaluation in a Phase 1b clinical trial in healthy volunteers.

Employing high-throughput screening of its proprietary chemical libraries, x-ray crystallography and medicinal chemistry, Lexicon scientists discovered and optimized a series of orally-administered, peripherally-acting small molecule inhibitors of the key enzyme responsible for producing serotonin in the gastrointestinal tract, tryptophan…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Lexicon Genetics Names Key Individuals to Lead Human Resources and Corporate...: Press release article from: PR Newswire January 5, 2001 700+ words
...Factors Affecting Forward-Looking Statements" in Lexicon's Quarterly Reports...Exchange Commission. Lexicon undertakes no obligation...update any such forward- looking statements. Contacts: For Lexicon Genetics: Jennifer Wolford...


Lexicon Genetics Announces Public Offering of Common Stock.: Press release article from: PR Newswire July 16, 2003 700+ words
...forward-looking statements" about Lexicon's current...Forward-Looking Statements" and "Business...Factors" in Lexicon's Annual...Commission. Lexicon undertakes...forward-looking statements, whether...


Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European...: Press release article from: PR Newswire March 5, 2009 700+ words
...forward-looking statements," including...relating to Lexicon's clinical...forward-looking statements relating to Lexicon's growth...Forward-Looking Statements" and "Risk Factors" in Lexicon's annual...


Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational...: Press release article from: PR Newswire October 15, 2007 700+ words
...information about Lexicon and its programs...contains "forward-looking statements," including statements relating to Lexicon's clinical development...contains forward-looking statements relating to Lexicon's growth and future...


Lexicon Advances LX1031 for Irritable Bowel Syndrome Into Phase 1b Clinical...: Press release article from: PR Newswire April 24, 2007 700+ words
...contains "forward-looking statements," including statements relating to Lexicon's regulatory filings...drug candidates in Lexicon's preclinical pipeline...contains forward-looking statements relating to Lexicon's growth and future...


Q2 2008 Lexicon Pharmaceuticals Inc. Earnings Conference Call - Final.: News wire article from: Fair Disclosure Wire July 29, 2008 700+ words
...forward-looking statements including...limitation, Lexicon's research...forward-looking statements relating to Lexicon's growth...may cause Lexicon's actual...forward-looking statements including...


Q3 2007 Lexicon Pharmaceuticals Inc. Earnings Conference Call - Final.: News wire article from: Fair Disclosure Wire October 30, 2007 700+ words
...forward-looking statements, including...limitation, Lexicon's research...forward-looking statements relating to Lexicon's growth...may cause Lexicon's actual...forward-looking statements, including...


Q3 2008 Lexicon Pharmaceuticals Inc. Earnings Conference Call -...: News wire article from: Fair Disclosure Wire October 30, 2008 700+ words
...forward-looking statements, including...limitation Lexicon's research...forward-looking statements relating to Lexicon's growth...may cause Lexicon's actual...forward-looking statements including...


Lexicon Achieves Second Performance Milestone in Genentech Alliance.: Press release article from: PR Newswire September 16, 2004 700+ words
...http://www.lexicon-genetics.com...contains "forward-looking statements," including statements about Lexicon's growth and...Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon's annual report...


Lexicon Genetics Announces Webcasts of Presentations at the CIBC World Markets...: Press release article from: PR Newswire October 31, 2001 700+ words
...website, www.lexicon-genetics.com...contains "forward-looking statements," including statements about Lexicon's growth and...Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon's annual report...

For more facts and information, see all results

Source: HighBeam Research, Lexicon Presents Class of Compounds Modulating TPH1, the Target for...

The AccessMyLibrary advertising network includes: